If you've looked at the prescribing information for Ozempic, Wegovy, or any GLP-1 medication, you've seen the warning: "Possible thyroid tumors, including cancer." It's a boxed warning—the FDA's most serious type. But what does it actually mean for your risk?
Here's the evidence-based answer: The warning is based on rodent studies, not human data. And the cancer type in question—medullary thyroid cancer—makes up only about 3% of all thyroid cancers. Let's break down what we know and don't know.
What the Black Box Warning Says
⚠️ FDA Black Box Warning
From the Ozempic prescribing information:
"In mice and rats, semaglutide caused a dose-dependent and treatment-duration-dependent increase in the incidence of thyroid C-cell tumors (adenomas and carcinomas) after lifetime exposure at clinically relevant plasma exposures."
"It is unknown whether OZEMPIC causes thyroid C-cell tumors, including medullary thyroid carcinoma (MTC), in humans as human relevance of semaglutide-induced rodent thyroid C-cell tumors has not been determined."
Key phrase: "It is unknown." The warning exists because of what happened in rodents. Whether this translates to humans remains an open question.
Why Rodents Get Thyroid Tumors (and Why Humans Might Not)
The thyroid cancer concern centers on a specific type: medullary thyroid cancer (MTC), which originates from parafollicular C cells. These cells produce calcitonin, a hormone involved in calcium regulation.
What Happened in Animal Studies
- Mice and rats given semaglutide for their entire lifetimes developed C-cell tumors
- The effect was dose-dependent and duration-dependent (more drug = more tumors)
- This happened at "clinically relevant plasma exposures" (drug levels similar to humans)
Why This May Not Apply to Humans
Rodent and human thyroid C cells respond very differently to GLP-1 receptor activation. Rats have many more GLP-1 receptors on their thyroid C cells than humans do. The mechanism that causes C-cell hyperplasia (the precursor to medullary thyroid cancer) in rodents may not occur—or may occur much less readily—in humans.
What the Human Data Shows
Systematic Review: 14,550 Patients
A 2024 systematic review (Feier et al.) analyzed 10 randomized controlled trials involving 14,550 participants, with 7,830 receiving semaglutide:
📊 Findings
Thyroid cancer incidence was notably low across all 10 studies, with isolated cases of papillary and medullary thyroid cancer each constituting less than 1% within study groups.
Conclusion: "Suggesting no significant risk for thyroid cancer associated with semaglutide use when considering the large sample sizes."
Large Population Studies
| Study | Findings |
|---|---|
| 2024 cohort study (1.6M patients) | GLP-1 agonists lowered risk of 10/13 obesity-related cancers vs. insulin |
| 2023 meta-analysis (37 trials + 19 real-world studies) | No increased risk of any cancer with semaglutide |
| 2025 meta-analysis (50 RCTs) | No significant difference in overall cancer risk |
The Nuance: Some Studies Show Mixed Results
Not all research is entirely reassuring:
- Some meta-analyses show a small overall increase in thyroid cancer (not just medullary)
- A French study found increased risk specifically for papillary thyroid cancer (the most common type)
- These studies don't always distinguish between cancer types
Medullary thyroid cancer (the type in the warning) accounts for only ~3% of all thyroid cancers. Most thyroid cancers are "differentiated" (papillary or follicular), which are generally very slow-growing and highly treatable. The research on differentiated thyroid cancer and GLP-1s is mixed, but even the increased risks found are small in absolute terms.
Who Should NOT Take GLP-1 Medications
Based on the FDA warning, these medications are contraindicated if you have:
Contraindications
- Personal history of medullary thyroid cancer (MTC)
- Family history of medullary thyroid cancer
- Multiple Endocrine Neoplasia syndrome type 2 (MEN2)—a genetic condition that increases MTC risk
If you fall into these categories, discuss alternative weight management options with your provider.
What About Papillary Thyroid Cancer?
The black box warning specifically mentions medullary thyroid cancer. But what about papillary thyroid cancer (the most common type)?
Dr. Haugen notes that papillary thyroid cancer is generally very slow-growing: "Ninety-five percent of small papillary thyroid cancers—tumors smaller than 1 centimeter—don't grow or cause trouble for patients."
Symptoms to Watch For
The FDA advises patients to tell their healthcare provider if they experience:
- A lump or swelling in the neck
- Hoarseness (persistent voice changes)
- Trouble swallowing
- Shortness of breath
These could be symptoms of thyroid tumors—though they can also be caused by many other, more common conditions.
Should You Get Thyroid Screening?
Interestingly, the FDA does not recommend routine monitoring with calcitonin testing (the blood marker for medullary thyroid cancer) in patients taking GLP-1s.
"The value of monitoring with serum calcitonin to detect medullary thyroid carcinoma is unclear. Such monitoring may increase the risk of unnecessary procedures, due to the low-test specificity for serum calcitonin and a high background incidence of thyroid disease."
In other words: screening healthy people could lead to more false positives and unnecessary biopsies than actual cancers caught.
The Obesity-Cancer Connection
When considering thyroid cancer risk, it's worth remembering that obesity itself is linked to at least 13 types of cancer. By helping with weight loss, GLP-1 medications may actually reduce overall cancer risk.
What We Still Don't Know
- Whether GLP-1 medications cause any thyroid cancer in humans (vs. rodents)
- Long-term thyroid cancer rates in people taking these drugs for 10+ years
- Whether the small increases in thyroid cancer seen in some studies are causal or correlational
- The exact mechanism differences between rodent and human thyroid C cells
The thyroid cancer black box warning on GLP-1 medications is based on rodent studies—not human data. The FDA requires this warning out of an abundance of caution because the human relevance is unknown.
What we know:
- In rodents, semaglutide causes thyroid C-cell tumors with lifetime exposure
- Human thyroid C cells respond very differently to GLP-1 activation
- Clinical trials and large population studies have not found significant thyroid cancer increases
- A 2024 systematic review of 14,550 patients found thyroid cancer incidence <1%
Who should avoid GLP-1s:
- Anyone with personal or family history of medullary thyroid cancer
- Anyone with MEN2 syndrome
For most people, current evidence suggests the thyroid cancer risk is theoretical rather than established. Discuss your individual risk factors with your healthcare provider.
Sources
- FDA. Ozempic Prescribing Information. 2025.
- Feier CVI, et al. "Assessment of Thyroid Carcinogenic Risk and Safety Profile of GLP1-RA Semaglutide (Ozempic) Therapy." Int J Mol Sci. 2024.
- Roswell Park Comprehensive Cancer Center. "Ozempic and thyroid cancer." September 2024.
- University of Colorado Cancer Center. "Does Using GLP-1 Drugs Increase Your Risk of Thyroid Cancer?" October 2025.
- Fred Hutch Cancer Center. "The new weight-loss drugs and cancer." March 2024.
- Drugs.com. "Does Ozempic cause cancer?" July 2025.
- Healthline. "Ozempic and cancer: Does the drug cause it?" August 2025.
Questions About GLP-1 Safety?
Compare providers offering comprehensive medical screening and monitoring.
Compare Providers →